Patients grouped by AD treatment
Twelve-hundred, thirty-seven patients with moderate-to-severe AD were
included in the analysis (age range 9-95 years). Patients were initially
grouped based on their AD treatment: 632 patients on dupilumab, 107
patients on other systemic treatments, and 498 patients on limited or no
treatment. The 107 patients on other systemics included 52 on
phototherapy, 29 on oral JAK inhibitors, 14 on prednisone, 6 on
methotrexate, 4 on cyclosporine, and 2 on mycophenolate mofetil. Among
patients on limited or no treatment, 354 were on topicals and 153 had no
treatment. Demographics, medication history, and comorbidities are
listed in Table 1A. No significant differences were found between groups
in terms of age and race.